Genomic Vision Achieves Major Milestone with Delivery of New High-Throughput Genome Analyzer to Quest Diagnostics
07 January 2015 - 6:00PM
Business Wire
- The new analyzer is designed to enable
the development of future lab-developed tests for hereditary
cancers and other complex diseases based on molecular combing
technology
- Goal of collaboration to extend
advanced cancer testing services to patients and physicians in the
United States
Genomic Vision (FR0011799907 – GV), a molecular
diagnostics company specialized in the development of diagnostic
tests for genetic diseases and cancers based on molecular combing,
today announces the delivery of a major milestone of its strategic
collaboration with Quest Diagnostics, the world’s leading provider
of diagnostic information services. Genomic Vision has delivered a
high-throughput genome analyzer now operational at the Quest
Diagnostics clinical laboratory in San Juan Capistrano, Calif.
Under terms of the collaboration, Quest Diagnostics has the right
to use the instrument to create an additional laboratory-developed
test for the detection of mutations in the BRCA gene, which can
cause hereditary breast and ovarian cancer, and other complex
diseases. The test would potentially supplement Quest’s BRCAvantage
suite of BRCA test services based on next-generation
sequencing.
Genomic Vision’s molecular combing technology allows the
fluorescent barcoding of multiple genes involved in disease
development giving each target gene a specific Genetic Morse Code.
The analyzer detects and identifies signature data coming from the
Genetic Morse Code. It provides a multiplexed solution to detect
genomic aberrations involved in complex diseases such as cancer,
muscular and neuronal development disorders.
The new analyzer was developed to increase throughput of
diagnostic screening volume and reduce turnaround times, for faster
results reporting.
In addition to BRCA, the collaborative terms also give Quest
Diagnostics the option to use the platform to accelerate the
development of lab-developed tests for other hereditary cancers,
such as Lynch syndrome or hereditary nonpolyposis colorectal
cancer, as well as spinal muscular atrophy.
Genomic Vision and Quest Diagnostics entered into a multi-year
exclusive collaboration based on Genomic Vision's proprietary
molecular combing genome-analysis technology in 2010. In 2013,
Quest Diagnostics introduced the first lab-developed test, for
FSHD, a debilitating myopathy, based on Genomic Vision’s technology
in the United States.
“This new platform has the potential to enable us to develop new
test services for improving clinical decisions involving of the
care of patients at risk of developing several serious pathologies,
such as hereditary breast cancer,” states Dr. Charles (Buck)
Strom, Medical Director of Quest Diagnostics Nichols
Institute.
“We are very pleased to offer, on time, to our US partner the
new genome analyzer. This achievement was made possible due to the
strong involvement of our teams and I would like to thank all our
employees that took part on this important challenge. Considering
the strong experience of Quest Diagnostics in developing CLIA
compliant tests, I’m very confident in their ability to continue
the development work that will bring to physicians and patients a
clinically important alternative to current genetic technologies,”
concludes Aaron Bensimon, Genomic Vision’s co-founder and
Chairman.
Next financial press release
- 2014 annual revenue, on January 15,
2015 (after market)
Genomic VisionAaron BensimonCo-founder, Chairman &
CEOTel.: +33 1 49 08 07
50investisseurs@genomicvision.comorNewCapInvestor Relations
/ Strategic CommunicationsDušan Orešanský / Emmanuel HuynhTel.: +33
1 44 71 94 92gv@newcap.fr
Visionary (NASDAQ:GV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Visionary (NASDAQ:GV)
Historical Stock Chart
From Jul 2023 to Jul 2024